| |
Article Title |
Author(s) |
Pages |
|
|
|
Welcome
|
David T. Bowen
|
v
|
|
|
|
Acknowledgements
|
|
vi
|
|
| Invited Presentations |
| |
Article Title |
Author(s) |
Pages |
|
|
|
1 A mouse model highlights a role for p53 in 5q− syndrome
|
J.L. Barlow,
L.F. Drynan,
N.L. Trim,
D.R. Hewett,
L.R. Holmes,
S. Lorenzo-Abalde,
A.L. Lane,
H.E. John,
R. Pannell,
S.H. Wong,
A.J. Warren,
W.N. Erber,
J.S. Wainscoat,
J. Boultwood,
A.N. McKenzie
et al.
|
S1
|
|
|
|
2 Morphological differentiation of hypocellular refractory cytopenia of childhood and severe aplastic anemia and clinical outcome
|
I. Baumann,
C. Niemeyer,
M. Ftihrer,
S. Behrendt,
V. Campr,
J. Csomor,
I. Furlan,
V. de Haas,
G. Kerndrup,
R.J. Leguit,
P. De Paepe,
P. Noellke,
S. Schwarz
et al.
|
S1
|
|
|
|
3 Morphologic criteria for defining granulocytic dysplasia in MDS
|
J.E. Goasguen,
B.J. Bain,
J.M. Bennett,
R. Brunning,
M. Tomonaga,
T. Vallespi
et al.
|
S2
|
|
|
|
4 Gene deletions and mutations in chronic myelomonocytic leukaemia
|
V. Gelsi-Boyer,
M. Brecqueville,
N. Cervera,
A. Murati,
N. Vey,
M.-J. Mozziconacci,
D. Birnbaum
et al.
|
S2
|
|
|
|
5 Thrombomimetic agents in myelodysplastic syndromes
|
H. Cherif
|
S2
|
|
|
|
6 New mutations in MDS/MPN
|
N.C.P. Cross
|
S2-S3
|
|
|
|
7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry
|
L. de Swart,
A. Smith,
P. Fenaux,
A. Symeonidis,
E. Hellström-Lindberg,
G. Sanz,
J. Cermak,
O. Georgescu,
U. Germing,
M. MacKenzie,
O. Beyne-Rauzy,
L. Malcovati,
R. Stauder,
J. Droste,
D. Bowen,
T. de Witte
et al.
|
S3
|
|
|
|
8 Standardization of flow cytometric analysis in myelodysplastic syndromes
|
M.G. Pella Porta
|
S3-S4
|
|
|
|
9 The added value of quality-of-life and other patient-reported outcomes in clinical research of patients with myelodysplastic syndromes
|
F. Efficace
|
S4
|
|
|
|
10 Guidelines for immunosuppression in MDS
|
P. Epling-Burnette,
A.F. List,
R.S. Komrokji
|
S4
|
|
|
|
11 Informed patients are “better” patients
|
P. Festy
|
S4-S5
|
|
|
|
12 Morphology is dead – long live morphology
|
U. Germing
|
S5
|
|
|
|
13 Molecular analysis as a diagnostic tool in myelodysplastic syndromes
|
T. Graubert
|
S5
|
|
|
|
14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM)
|
P. Greenberg,
H. Tuechler,
J. Schanz,
F. Sole,
J.M. Bennett,
G. Garcia-Manero,
A. Levis,
L. Malcovati,
M. Cazzola,
G. Sanz,
J. Cermak,
C. Fonatsch,
M. LeBeau,
M. Slovak,
O. Krieger,
M. Luebbert,
S. Magalhaes,
Y. Miyazaki,
M. Pfeilstocker,
M. Sekeres,
J. Maciejewski,
R. Stauder,
S. Tauro,
A. van de Loosdrecht,
U. Germing,
P. Fenaux,
D. Haase
et al.
|
S6
|
|
|
|
15 Introduction to epigenetic regulation
|
K. Grønbæk
|
S6
|
|
|
|
16 Recent advances in cytogenetic risk scoring in MDS
|
D. Haase,
J. Schanz
|
S6-S7
|
|
|
|
17 MDS UK patient support group
|
D. Hall
|
S7
|
|
|
|
18 Prognostic impact of TP53 mutations in MDS with del(5q)
|
M. Jadersten
|
S7
|
|
|
|
19 Debate: Lenalidomide is the standard of care for the management of isolated del 5(q) MDS
|
M. Jadersten
|
S7-S8
|
|
|
|
20 Ectopic innate immune signaling in marrow cells results in an MDS phenotype
|
A. Karsan
|
S8
|
|
|
|
21 Conditioning regimen for allogeneic stem cell transplantation in MDS
|
N. Kröger
|
S8
|
|
|
|
22 Risk analysis in the treatment of myelodysplastic syndromes in the elderly
|
S.E. Kurtin
|
S8-S9
|
|
|
|
23 International research activity in MDS – novel therapeutics
|
A. List
|
S9
|
|
|
|
24 New prognostic scores
|
L. Malcovati
|
S9
|
|
|
|
25 Acute myeloid leukemia and hematopoietic lineage commitment
|
C. Nerlov
|
S9
|
|
|
|
26 Juvenile myelomonocytic leukemia: How many entities?
|
C.M. Niemeyer
|
S9-S10
|
|
|
|
27 Molecular pathogenesis of the 5q- syndrome
|
A. Pellagatti
|
S10
|
|
|
|
28 Optimising pre and post transplant management
|
U. Platzbecker
|
S10
|
|
|
|
29 Deconstructing niche contributions to myelodysplasia in mice
|
M.H.G.P. Raaijmakers
|
S10
|
|
|
|
30 Allogeneic stem cell transplantation from alternative stem cell sources in myelodysplastic syndromes
|
G. Sanz
|
S10-S11
|
|
|
|
31 Cytogenetics – for how much longer?
|
B. Schlegelberger
|
S11
|
|
|
|
32 Patient-doctor relationship – perceptions
|
M.A. Sekeres
|
S11
|
|
|
|
33 Optimising combination strategies
|
M.A. Sekeres
|
S11-S12
|
|
|
|
34 Health-related quality of life in low-risk MDS patients from the European LeukemiaNet Registry: Correlation with age, gender and decreased survival
|
R. Stauder,
A. Smith,
T. de Witte,
J. Proste,
P. Fenaux,
A. Symeonidis,
E. Hellstrom-Lindberg,
G. Sanz,
J. Cermak,
O. Georgescu,
U. Germing,
M. Mac Kenzie,
O. Beyne-Rauzy,
L. Malcovati,
D. Bowen
et al.
|
S12
|
|
|
|
35 Debate: “Iron chelation therapy, as recommended in National MDS Management Guidelines, is an established standard of care” – contrarian position
|
D.P. Steensma
|
S12
|
|
|
|
36 Questions patients with MDS often ask their doctors
|
D.P. Steensma
|
S12-S13
|
|
|
|
37 Hematopoietic stem cells and leukemia in the niche
|
T. Suda
|
S13
|
|
|
|
38 Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome
|
A.J. Finch,
C. Hilcenko,
N. Basse,
L. Drynan,
B. Goyenechea,
T.F. Menne,
Á. González Fernández,
P. Simpson,
C.S. D'Santos,
M.J. Arends,
J. Donadieu,
C. Bellanné-Chantelot,
M. Costanzo,
C. Boone,
A.N. McKenzie,
S.M. Freund,
A.J. Warren
et al.
|
S13
|
|
|
|
39 Myeloid-derived suppressor cells (MDSC) are effectors of bone marrow suppression in lower risk myelodysplastic syndromes (MDS)
|
S. Wei,
X. Chen,
K. McGraw,
J. Zhou,
P.K. Burnette,
H. Wang,
J. Djeu,
D. Gabrilovich,
A. List
et al.
|
S13
|
|
| Oral Presentations |
| |
Article Title |
Author(s) |
Pages |
|
|
|
40 Spontaneous abrogation of a DNA damage checkpoint has clinical benefit but promotes MDS/AML in Fanconi anemia
|
R. Ceccaldi,
D. Briot,
J. Larghero,
N. Vasquez,
M.-E. Noguera,
Q. Waisfisz,
C. Pondarre,
T. Leblanc,
E. Gluckman,
H. Joenje,
D. Stoppa-Lyonnet,
G. Socie,
J. Soulier
et al.
|
S14
|
|
|
|
41 Profiling and characterizing aberrant DNA and histone methylations of lineage-determining factor encoding genes RUNX1, SPIB and SPI1 in myelodysplastic syndrome
|
J.X. Cheng,
J. Anastasi,
E. Kleinbrink,
S.-S. Kim,
J.Q. Shen,
J.W. Vardiman
et al.
|
S14-S15
|
|
|
|
42 MicroRNA changes in patients with IPSS lower-risk myelodysplastic syndromes and del5q undergoing treatment with lenalidomide
|
M. Cuzzola,
R. Latagliata,
M.A. Aloe Spiriti,
F. Nobile,
A. Cortelezzi,
C. Finelli,
G. Sanpaolo,
G. Palumbo,
M. Breccia,
F. Di Raimondo,
G. Alimena,
E.N. Oliva
et al.
|
S15
|
|
|
|
43 The broad use of erythropoietic stimulating agents (ESA) for myelodysplastic syndromes (MDS) in the U.S. is not consistent with guidelines
|
A.J. Davidoff,
M.R. Baer,
S.R. Weiss Smith,
X. Ke,
J. Bierenbaum,
F. Hendrick,
D. McNally,
S.D. Gore
et al.
|
S15
|
|
|
|
44 FAS gene expression is epigenetically regulated and predicts the responsiveness to azacitidine in high-risk myelodysplastic syndromes
|
S. Ettou,
C. Humbrecht,
B. Benet,
O. Kosmider,
N. Drain,
O. Beyne-Rauzy,
B. Quesnel,
C. Lacombe,
F. Dreyfus,
P. Mayeux,
E. Solary,
M. Fontenay
et al.
|
S16
|
|
|
|
45 Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: A single cell study
|
L. Garderet,
L. Kobari-abbassi,
C. Mazurier,
C. De Witte,
M.C. Giarratana,
C. Perot,
N.C. Gorin,
H. Lapillonne,
L. Douay
et al.
|
S16
|
|
|
|
46 Novel role of p15Ink4b tumor suppressor in erythropoiesis and hematopoietic homeostasis
|
R. Humeniuk,
M. Rosu-Myles,
L. Wolff
|
S16-S17
|
|
|
|
47 Chromosomal complexity in primary myelodysplastic syndromes (MDS) in Nagasaki atomic bomb survivors
|
M. Iwanaga,
Y. Miyazaki,
T. Hata,
H. Tsushima,
J. Taguchi,
D. Imanishi,
Y. Imaizumi,
T. Fukushima,
K. Tsukasaki,
M. Tomonaga
et al.
|
S17
|
|
|
|
48 Next-generation sequencing technology combined with multiplexed barcoded samples of myelodysplastic syndromes reveals an abundance of target gene mutations
|
Y. Nagata,
M. Sanada,
K. Yoshida,
H. Mori,
L.-Y. Shin,
H.P. Koeffler,
S. Ogawa
et al.
|
S17
|
|
|
|
49 ABCB7 plays an essential role in sideroblast formation in acquired refractory anemia with ring sideroblasts
|
M. Nikpour,
A. Liu,
C. Scharenberg,
K. Högstrand,
S. Conte,
M. Jansson,
A.-M. Forsblom,
A. Grandien,
E. Hellström-Lindberg
et al.
|
S17-S18
|
|
|
|
50 The identification of novel somatic mutations in MDS by whole exome sequencing
|
E. Papaemmanuil,
A. Cvejic,
L. Mudie,
S. Melaren,
K. Raine,
D. Jones,
A. Godfrey,
E. Baxter,
L. Malcovati,
N.C. Cross,
E. Hellstrom Lindberg,
C. Gambacorty Passerini,
J. Wainscoat,
T. Green,
A.P. Futreal,
M.R. Stratton,
J. Boultwood,
P. Vyas,
D. Bowen,
M. Cazzola,
P.J. Campbell
et al.
|
S18
|
|
|
|
51 Transcription Intermediary Factor 1 gamma (TIF1γ) is an epigenetically-regulated tumor suppressor gene in human chronic myelomonocytic leukemia
|
N. Droin,
R. Aucagne,
J. Paggetti,
B. Lagrange,
A. Largeot,
L. Martin,
P. Fenaux,
R. Losson,
E. Solary,
J.-N. Bastie,
L. Delva
et al.
|
S18
|
|
|
|
52 Chromatin structure at PU.l gene and cell differentiation capacity in myelodysplastic syndrome treated by 5-azacytidine
|
T. Stopka,
N. Curik,
P. Burda,
K. Vargova,
V. Pospisil,
H. Hajkova,
F. Sawulidi,
E. Necas,
M. Belickova,
C. Haskovec,
J. Cermak,
M. Trneny,
A. Jonasova
et al.
|
S19
|
|
|
|
53 The role of p53 in the cytopenias of NUP98-HOXD13 driven MDS and its progression to acute leukemia
|
H. Xu,
S. Menendez,
S. Nimer
|
S19
|
|
|
|
54 Terminal effector memory T cell expansion: Biomarker for lenalidomide resistance in myelodysplastic syndrome
|
L. Zhang,
J. Zou,
J. Fulp,
D.-T. Chen,
F. Bai,
J.S. Painter,
S. Wei,
R. Komrokji,
A. List,
P.K. Epling-Burnette
et al.
|
S19-S20
|
|
|
|
55 Independent validation of the MDS Comorbidity Score (MDS-CI)
|
E. Zipperer,
N. Tanha,
A. Kündgen,
F. Fox,
C. Strupp,
R. Haas,
N. Gattermann,
U. Germing
et al.
|
S20
|
|
|
|
56 Six new prognostic markers determined using gene expression profiling, separate chronic myelomonocytic leukaemia in two distinct subtypes
|
E. Bou Samra,
J. Moreaux,
F. Rufflé,
D. Piquemal,
A. Boureux,
E. Jourdan,
T. Commes
et al.
|
S20
|
|
|
|
57 How to assess the medullary blast count in MDS? Pay attention to the proportion of erythroid cells!
|
U. Germing,
J. Neukirchen,
C. Strupp,
K. Bach,
M. Wulfert,
R. Haas,
A.A. Giagounidis,
C. Aul,
N. Gattermann
et al.
|
S20-S21
|
|
|
|
58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients
|
A. Giagounidis,
E. Hellström-Lindberg,
P. Fenaux,
J. Backstrom,
T. Fu,
A. List
et al.
|
S21
|
|
